TY - JOUR
T1 - Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines
AU - Nabors, Louis Burt
AU - Portnow, Jana
AU - Ammirati, Mario
AU - Baehring, Joachim
AU - Brem, Henry
AU - Butowski, Nicholas
AU - Fenstermaker, Robert A.
AU - Forsyth, Peter
AU - Hattangadi-Gluth, Jona
AU - Holdhoff, Matthias
AU - Howard, Steven
AU - Junck, Larry
AU - Kaley, Thomas
AU - Kumthekar, Priya
AU - Loeffler, Jay S.
AU - Moots, Paul L.
AU - Mrugala, Maciej M.
AU - Nagpal, Seema
AU - Pandey, Manjari
AU - Parney, Ian
AU - Peters, Katherine
AU - Puduvalli, Vinay K.
AU - Ragsdale, John
AU - Rockhill, Jason
AU - Rogers, Lisa
AU - Rusthoven, Chad
AU - Shonka, Nicole
AU - Shrieve, Dennis C.
AU - Sills, Allen K.
AU - Swinnen, Lode J.
AU - Tsien, Christina
AU - Weiss, Stephanie E.
AU - Wen, Patrick Yung
AU - Willmarth, Nicole E.
AU - Bergman, Mary Anne
AU - Engh, Anita
N1 - Publisher Copyright:
© JNCCN - Journal of the National Comprehensive Cancer Network.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas.
AB - For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas.
KW - Antineoplastic Combined Chemotherapy Protocols/standards
KW - Biomarkers, Tumor/analysis
KW - Central Nervous System Neoplasms/classification
KW - Combined Modality Therapy/methods
KW - Glioma/classification
KW - Humans
KW - Neoadjuvant Therapy/methods
KW - Neoplasm Grading
KW - Nervous System/pathology
KW - Prognosis
KW - Radiotherapy/methods
UR - http://www.scopus.com/inward/record.url?scp=85033793575&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2017.0166
DO - 10.6004/jnccn.2017.0166
M3 - Article
C2 - 29118226
SN - 1540-1405
VL - 15
SP - 1331
EP - 1345
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 11
ER -
